Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies

Pancreatic ductal adenocarcinoma (PDAC) exhibits a variety of phenotypes with regard to disease progression and treatment response. This variability complicates clinical decision-making despite the improvement of survival due to the recent introduction of FOLFIRINOX (FFX) and nab-paclitaxel. Questio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Kimiyo N., Nakamura, Akira, Liu, Lin L., Stein, Shayna, Tramontano, Angela C., Kartoun, Uri, Shimizu, Tetsunosuke, Inoue, Yoshihiro, Asakuma, Mitsuhiro, Haeno, Hiroshi, Kong, Chung Yin, Uchiyama, Kazuhisa, Gonen, Mithat, Hur, Chin, Michor, Franziska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485645/
https://www.ncbi.nlm.nih.gov/pubmed/31026288
http://dx.doi.org/10.1371/journal.pone.0215409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485645/
https://www.ncbi.nlm.nih.gov/pubmed/31026288
http://dx.doi.org/10.1371/journal.pone.0215409

Ejemplares similares